Leticia Hernandez Davila, MD
Endocrinology, Diabetes & Metabolism · Carolina, PRNPI 1750573408
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (45.6%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 43.7% of the total. Reporting peaked in 2021 at $10,520 and has fallen 80.2% since, to $2,083 in 2025.
Across 247 payments — averaging $109.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$12K
- AbbVie$4K
- Johnson & Johnson$2K
- Bayer$2K
- Amgen$1K
- Merck$1K
- plus $5K from 14 others
What the payments were for
- Consulting fees$5,67021%
- Speaking & faculty fees$8,23631%
- Travel & lodging$5362%
- Food & beverage$12,31646%
- Education$2361%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 66 | $11,800 |
| AbbVie | 10 | $3,654 |
| Johnson & Johnson | 5 | $2,175 |
| Bayer | 23 | $1,643 |
| Amgen | 13 | $1,476 |
| Merck | 12 | $1,359 |
| Medtronic(2 entities) | 22 | $1,095 |
| Novo Nordisk | 25 | $1,054 |
| Boehringer Ingelheim | 23 | $975 |
| AstraZeneca | 26 | $768 |
| Abbott | 4 | $161 |
| Dexcom, Inc. | 3 | $142 |
| Kyowa Kirin, Inc. | 1 | $119 |
| Lilly USA, LLC | 1 | $119 |
| BETA Bionics, Inc. | 1 | $116 |
| PBG Puerto Rico LLC | 4 | $90 |
| Eli Lilly Export S.A. Puerto Rico Branch | 5 | $84 |
| Corcept Therapeutics | 1 | $75 |
| Perspectum Diagnostics Ltd | 1 | $73 |
| Pfizer Pharmaceuticals LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$6,622
- TOUJEO$3,848
- Synthroid$3,083
- INVOKANA$2,076
- TZIELD$1,144
- Kerendia$1,090
- STEGLATRO$1,050
- Repatha$499
- EVENITY$494
- JARDIANCE$484
- MINIMED 780G$402
- iLet Bionic Pancreas$347
- SOTAGLIFLOZIN$300
- Prolia$250
- Wegovy$234
- FARXIGA$230
- TEPEZZA$141
- LANTUS$135
- MOUNJARO$119
- CRYSVITA$119
How this compares
$26,994 in reported general payments places this provider in the 85th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
See all endocrinology, diabetes & metabolism providers in Puerto Rico →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 126 | $87,699 |
| MounjaroTirzepatide | 61 | $67,622 |
| TrulicityDulaglutide | 59 | $65,980 |
| JardianceEmpagliflozin | 87 | $63,354 |
| OzempicSemaglutide | 50 | $62,712 |
| FarxigaDapagliflozin Propanediol | 79 | $59,650 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 73 | $48,106 |
| SynthroidLevothyroxine Sodium | 854 | $45,135 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 37 | $33,076 |
| JanuviaSitagliptin Phosphate | 26 | $23,283 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 28 | $21,694 |
| KerendiaFinerenone | 26 | $17,141 |
| GlyxambiEmpagliflozin/Linagliptin | 26 | $16,027 |
| Xigduo XrDapaglifloz Propaned/Metformin | 22 | $11,139 |
| Humalog Kwikpen U-100Insulin Lispro | 52 | $10,350 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTrijardy Xr, Jardiance, Synjardy Xr, Glyxambi | $975 | $188,774267 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog Mix 75-25, Humalog, Humulin 70-30 | $119 | $145,413209 claims |
| MerckJanumet Xr, Januvia | $1,359 | $71,38999 claims |
| Novo NordiskOzempic, Novolog | $1,054 | $64,32861 claims |
| AstraZenecaFarxiga | $768 | $59,65079 claims |
| AbbVieSynthroid | $3,654 | $45,135854 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $11,800 | $41,079119 claims |
| BayerKerendia | $1,643 | $17,14126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
Other endocrinology, diabetes & metabolism in Carolina
- Jose Garcia MateoPonce$945K
- Manuel Alegre-HernandezSan Juan$156K
- Monica Ortiz-RiveraSan Juan$148K
- Alex Gonzalez BossoloSan Juan$110K
- Michelle Mangual GarciaSan Juan$87K
- Meliza Martinez RodriguezSan Juan$80K
- Milliette Alvarado SantiagoRio Piedras$75K
- Altagracia Alcantara GonzalezBayamon$58K
- Jean Pujals KuryBayamon$50K
- Rafael GonzalezRio Piedras$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.